Candel Therapeutics to Hold Online R&D Event on December 5, 2025

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Nov 17 2025

0mins

Source: Globenewswire

Candel Therapeutics R&D Event Announcement: Candel Therapeutics will host a virtual Research and Development Day on December 5, 2025, featuring presentations and discussions on their viral immunotherapy approach and oncology pipeline.
Key Presentations and Panel Discussions: The event will include insights from Candel's leadership and notable experts in immuno-oncology, covering topics such as CAN-2409 for prostate cancer and CAN-3110 for glioblastoma.
Overview of CAN-2409 and CAN-3110: CAN-2409 is a leading biological immunotherapy candidate targeting various solid tumors, while CAN-3110 is a next-generation oncolytic viral therapy currently in clinical trials for recurrent glioblastoma.
Regulatory Designations and Clinical Progress: Both CAN-2409 and CAN-3110 have received Fast Track and Orphan Drug Designations from the FDA, with ongoing clinical trials showing promising results and tolerability.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free